| Not Yet Recruiting | Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by F NCT07506967 | Kenya Medical Research Institute | N/A |
| Not Yet Recruiting | Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis NCT07149753 | Universidad Industrial de Santander | Phase 1 |
| Recruiting | Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis NCT06798415 | Hayder Adnan Fawzi | Phase 2 |
| Recruiting | Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis NCT06797544 | Hayder Adnan Fawzi | Phase 2 |
| Recruiting | Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stiboglu NCT06798402 | Al-Mustafa University College | Phase 2 |
| Not Yet Recruiting | Feasibility of Integrating Thermotherapy for Treatment of Cutaneous Leishmaniasis in Primary Health Care Setup NCT06746350 | Armauer Hansen Research Institute, Ethiopia | N/A |
| Completed | Epidemiology of Cutaneous Leishmaniasis in Niger, Mali, Togo : Mapping of Clinical Cases, Species, Reservoirs NCT06692985 | Centre Hospitalier de Cayenne | — |
| Completed | Documentation of Patient Outcomes for SSG/Allopurinol Combination Treatment in Ethiopia NCT04699383 | Institute of Tropical Medicine, Belgium | — |
| Completed | Miltefosine and GM-CSF in Cutaneous Leishmaniasis NCT03023111 | Hospital Universitário Professor Edgard Santos | Phase 3 |
| Completed | Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in th NCT02687971 | Drugs for Neglected Diseases | Phase 2 |
| Completed | Accuracy of a Rapid Diagnostic Test for Cutaneous Leishmaniasis in Morocco NCT02979002 | National School of Public Health, Morocco | — |
| Unknown | Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli P NCT02281669 | Sheba Medical Center | — |
| Completed | Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia NCT01845727 | Drugs for Neglected Diseases | Phase 1 / Phase 2 |
| Terminated | High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus NCT01953744 | Hospital Universitário Professor Edgard Santos | Phase 3 |
| Completed | WR 279,396 for the Treatment of Cutaneous Leishmaniasis NCT01988909 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis i NCT01790659 | U.S. Army Medical Research and Development Command | Phase 3 |
| Completed | Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis NCT01381055 | Paulo Roberto Lima Machado | Phase 2 / Phase 3 |
| Terminated | WR 279,396 Open Label Treatment Protocol in Tunisia NCT01494350 | U.S. Army Medical Research and Development Command | Phase 2 |
| Completed | Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis NCT01464242 | Centro Internacional de Entrenamiento e Investigaciones Médicas | Phase 2 / Phase 3 |
| Completed | Pharmacokinetics of Miltefosine in Children and Adults NCT01462500 | Centro Internacional de Entrenamiento e Investigaciones Médicas | Phase 4 |
| Completed | Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis NCT01050777 | Tehran University of Medical Sciences | EARLY_Phase 1 |
| Completed | Intralesional Antimony for Bolivian Cutaneous Leishmaniasis NCT01300975 | Fundacion Nacional de Dermatologia | Phase 2 |
| Completed | Miltefosine to Treat Mucocutaneous Leishmaniasis NCT01050907 | Knight Therapeutics (USA) Inc | Phase 2 |
| Completed | A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis NCT01011309 | Access to Advanced Health Institute (AAHI) | Phase 2 |
| Unknown | Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis NCT00840359 | Hadassah Medical Organization | Phase 2 |
| Unknown | Frequency of Parasite Infection in Hyraxes and Sandflies During Outbreak of Leishmania Tropica Epidemic in The NCT00737386 | Hadassah Medical Organization | — |
| Completed | Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India NCT01661296 | Sarder Patel Medical College | Phase 4 |
| Completed | Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis NCT01301924 | Oswaldo Cruz Foundation | Phase 2 / Phase 3 |
| Completed | Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen NCT00633009 | Nielsen BioSciences, Inc. | Phase 2 |
| Terminated | Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis NCT00682656 | Ana Rabello | Phase 2 / Phase 3 |
| Completed | Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis NCT01380314 | Foundation Fader | Phase 2 |
| Completed | Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) NCT00606580 | U.S. Army Medical Research and Development Command | Phase 3 |
| Unknown | Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia NCT00487253 | Centro Internacional de Entrenamiento e Investigaciones Médicas | Phase 3 |
| Completed | Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthropono NCT04340128 | Tehran University of Medical Sciences | Phase 3 |
| Completed | Cosmetic Outcome of Leishmaniasis Scar After WR279396 Application NCT00490230 | U.S. Army Medical Research and Development Command | N/A |
| Terminated | Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony NCT01380301 | Foundation Fader | Phase 2 |
| Terminated | Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396 NCT00657917 | U.S. Army Medical Research and Development Command | Phase 2 |
| Completed | Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia. NCT00471705 | Universidad de Antioquia | Phase 3 |
| Terminated | Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmanias NCT00317629 | Fundación Cardiovascular de Colombia | Phase 3 |
| Completed | Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica NCT00351520 | Tehran University of Medical Sciences | Phase 3 |
| Completed | Surveillance for Leishmaniasis Skin Lesions in Mali NCT00344084 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis NCT00317980 | University of Brasilia | Phase 4 |
| Completed | Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis NCT00257530 | Drugs for Neglected Diseases | Phase 3 |
| Completed | Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia NCT00233545 | AB Foundation | Phase 2 |
| Completed | Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healt NCT00121849 | Access to Advanced Health Institute (AAHI) | Phase 1 |
| Completed | Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Paras NCT00121862 | Access to Advanced Health Institute (AAHI) | Phase 2 |
| Completed | Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis NCT00884377 | U.S. Army Medical Research and Development Command | Phase 2 |
| Completed | Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmania NCT00973128 | Hospital Universitário Professor Edgard Santos | Phase 2 |
| Completed | Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World NCT00703924 | U.S. Army Medical Research and Development Command | Phase 2 |
| Completed | Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and NCT00001906 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Available | Pilot Study Using a Heat Pack to Treat Cutaneous Leishmaniasis NCT01277796 | Universidad Peruana Cayetano Heredia | — |